Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ZUG, SWITZERLAND AND BOSTON, MARCH 11, 2026 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS AG (NASDAQ: CRSP) (THE COMPANY) TODAY ANNOUNCED THE PRICING OF $550 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS CONVERTIBLE SENIOR NOTES DUE 2031 (THE NOTES) IN A PRIVATE OFFERING (THE OFFERING) TO PERSONS REASONABLY BELIEVED TO BE QUALIFIED INSTITUTIONAL BUYERS PURSUANT TO RULE 144A UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT). THE COMPANY ALSO GRANTED THE INITIAL PURCHASERS OF THE NOTES AN OPTION TO PURCHASE, FOR SETTLEMENT WITHIN A PERIOD OF 13 DAYS FROM, AND INCLUDING, THE DATE THE NOTES ARE FIRST ISSUED, UP TO AN ADDITIONAL $50 MILLION AGGREGATE PRINCIPAL AMOUNT OF THE NOTES.

CRISPR THERAPEUTICS PRICES UPSIZED CONVERTIBLE SENIOR NOTES OFFERING

ZUG, SWITZERLAND AND BOSTON, MARCH 10, 2026 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS AG (NASDAQ: CRSP) (THE COMPANY) TODAY ANNOUNCED ITS INTENTION TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $350 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS CONVERTIBLE SENIOR NOTES DUE 2031 (THE NOTES) IN A PRIVATE OFFERING (THE OFFERING) TO PERSONS REASONABLY BELIEVED TO BE QUALIFIED INSTITUTIONAL BUYERS PURSUANT TO RULE 144A UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT). THE COMPANY ALSO EXPECTS TO GRANT THE INITIAL PURCHASERS OF THE NOTES AN OPTION TO PURCHASE, FOR SETTLEMENT WITHIN A PERIOD OF 13 DAYS FROM, AND INCLUDING, THE DATE THE NOTES ARE FIRST ISSUED, UP TO AN ADDITIONAL $52.5 MILLION AGGREGATE PRINCIPAL AMOUNT OF THE NOTES.

CRISPR THERAPEUTICS ANNOUNCES PROPOSED CONVERTIBLE SENIOR NOTES OFFERING

ZUG, SWITZERLANDANDBOSTON, FEB. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS (NASDAQ: CRSP) TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. AS WE CLOSE OUT THE FOURTH QUARTER, CRISPR THERAPEUTICS CONTINUES TO MAKE STEADY PROGRESS ACROSS A BROAD AND INCREASINGLY MATURE PIPELINE, SAIDSAMARTH KULKARNI, PH.D.

CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

-2026 IS POISED TO BE A DATA- AND MILESTONE-RICH YEAR ACROSS THE PORTFOLIO- -CASGEVY  LAUNCH ACCELERATION CONTINUES, SUPPORTING MULTI-BILLION-DOLLAR POTENTIAL- -BROAD PIPELINE SUPPORTED BY LEADING GENE-EDITING AND SIRNA PLATFORMS ACROSS CARDIOVASCULAR, AUTOIMMUNE, ONCOLOGY AND RARE DISEASES- -STARTING 2026 WITH A STRONG BALANCE SHEET WITH APPROXIMATELY$2 BILLIONIN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES- ZUG, SWITZERLANDANDBOSTON, JAN. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS(NASDAQ: CRSP), A BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATING TRANSFORMATIVE GENE-BASED MEDICINES FOR SERIOUS DISEASES, TODAY HIGHLIGHTED ITS STRATEGIC PRIORITIES AND ANTICIPATED 2026 MILESTONES. "ENTERING 2026, CRISPR THERAPEUTICS IS WELL POSITIONED, WITH CASGEVY GAINING MOMENTUM, AND MULTIPLE PROGRAMS WITH ENCOURAGING DATA ADVANCING RAPIDLY THROUGH CLINICAL TRIALS ACROSS A DIVERSE SET OF THERAPEUTIC AREAS, SAID SAMARTH KULKARNI, PH.D.

CRISPR THERAPEUTICS HIGHLIGHTS STRATEGIC PRIORITIES AND ANTICIPATED 2026 MILESTONES

ZUG, SWITZERLANDANDBOSTON, JAN. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS (NASDAQ: CRSP), A BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATING TRANSFORMATIVE GENE-BASED MEDICINES FOR SERIOUS DISEASES, TODAY ANNOUNCED THAT MEMBERS OF ITS SENIOR MANAGEMENT TEAM WILL PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON MONDAY, JANUARY 12, 2026 AT 8:15 A.M.

CRISPR THERAPEUTICS TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

-FOUR AUTOIMMUNE PATIENTS TREATED TO DATE DEMONSTRATE DEEP B-CELL DEPLETION SUSTAINED FOR AT LEAST 28 DAYS; INITIAL EFFICACY DATA SUGGEST SIGNIFICANT CLINICAL IMPROVEMENT IN PATIENTS DOSED AT THE 100 MILLION CELL DOSE, WITH THE FIRST SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT ACHIEVING DEFINITIONS OF REMISSION IN SLE (DORIS) REMISSION THROUGH MONTH 6-

CRISPR THERAPEUTICS PROVIDES BROAD UPDATE ON ZUGOCAPTAGENE GELEUCEL (ZUGO-CEL; FORMERLY CTX112) IN AUTOIMMUNE DISEASES AND HEMATOLOGIC MALIGNANCIES

-POSITIVE PHASE 1 DATA FOR CTX310  PRESENTED IN A LATE-BREAKING PRESENTATION AT THE AMERICAN HEART ASSOCIATION (AHA) SCIENTIFIC SESSIONS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE- -CASGEVY  MOMENTUM ACCELERATING; NEARLY 300 PATIENTS HAVE BEEN REFERRED TO AUTHORIZED TREATMENT CENTERS (ATCS), APPROXIMATELY 165 PATIENTS HAVE COMPLETED THEIR FIRST CELL COLLECTION AND 39 HAVE RECEIVED INFUSIONS ACROSS ALL REGIONS; VERTEX EXPECTS CLEAR LINE OF SIGHT TO OVER $100 MILLION IN TOTAL CASGEVY REVENUE THIS YEAR AND SIGNIFICANT GROWTH EXPECTED IN 2026- -PEDIATRIC DEVELOPMENT OF EXA-CEL IS ADVANCING IN SCD AND TDT, WITH ENROLLMENT IN TWO GLOBAL PHASE 3 STUDIES COMPLETED; INITIAL DATA WILL BE PRESENTED AT THE UPCOMING AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING- -CLINICAL TRIALS ONGOING FOR CTX112, TARGETING CD19, ACROSS MULTIPLE INDICATIONS; BROAD UPDATES FOR CTX112 IN AUTOIMMUNE DISEASE AND ONCOLOGY EXPECTED BY YEAR-END- -PRECLINICAL DATA FOR CTX460, PRESENTED AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) ANNUAL CONGRESS, DEMONSTRATED IN VIVO GENE CORRECTION OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) WITH A POTENTIAL BEST-IN-CLASS PROFILE; CLINICAL TRIAL INITIATION PLANNED FOR MID-2026- -PHASE 2 CLINICAL TRIAL ONGOING FOR SRSD107, TARGETING FACTOR XI FOR THE PREVENTION OF THROMBOEMBOLIC DISORDERS; FIRST PATIENT DOSED AND TRIAL EXPANDED TO ADDITIONAL SITES IN EUROPE- -STRONG BALANCE SHEET WITH APPROXIMATELY$1.9 BILLIONIN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OFSEPTEMBER 30, 2025- ZUG, SWITZERLANDANDBOSTON, NOV. 10, 2025 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS(NASDAQ: CRSP), A BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATING TRANSFORMATIVE GENE-BASED MEDICINES FOR SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. "THIS HAS BEEN ANOTHER STRONG QUARTER OF EXECUTION AND PROGRESS ACROSS OUR PORTFOLIO, SAID SAMARTH KULKARNI, PH.D.

CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

-DATA PRESENTED IN A LATE-BREAKING PRESENTATION AT THE AMERICAN HEART ASSOCIATION (AHA) SCIENTIFIC SESSIONS 2025- -PHASE 1 CLINICAL DATA FOR CTX310 DEMONSTRATE ROBUST, DOSE-DEPENDENT REDUCTIONS IN CIRCULATING ANGPTL3 WITH A MEAN REDUCTION FROM BASELINE OF -73% (MAXIMUM -89%), A MEAN REDUCTION IN TRIGLYCERIDES (TG) OF -55% (MAXIMUM -84%), AND A MEAN REDUCTION OF LOW-DENSITY LIPOPROTEIN (LDL) OF -49% (MAXIMUM -87%) AT THE HIGHEST DOSE- -AMONG PARTICIPANTS WITH ELEVATED BASELINE TG (>150 MG/DL), A MEAN REDUCTION OF 60% IN TG WERE OBSERVED AT THERAPEUTIC DOSES- -CTX310 WAS WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND NO GRADE 3 CHANGES IN LIVER TRANSAMINASES- -FINDINGS SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE ENTITLED FIRST-IN-HUMAN PHASE 1 TRIAL OF CRISPR-CAS9 GENE EDITING TARGETING ANGPTL3- ZUG, SWITZERLAND AND BOSTON, NOV. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS(NASDAQ: CRSP), A BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATING TRANSFORMATIVE GENE-BASED MEDICINES FOR SERIOUS DISEASES, TODAY ANNOUNCEDPOSITIVE PHASE 1 DATA FROM ITS ONGOING CLINICAL TRIAL EVALUATING CTX310, AN INVESTIGATIONAL, IN VIVO CRISPR/CAS9 GENE-EDITING THERAPY TARGETING ANGPTL3. A SINGLE-COURSE TREATMENT WITH CTX310 PRODUCED DOSE-DEPENDENT, DURABLE REDUCTIONS IN CIRCULATING ANGPTL3 WITH A MEAN REDUCTION FROM BASELINE OF -73% (MAXIMUM -89%), A MEAN REDUCTION IN TRIGLYCERIDES (TG) OF -55% (MAXIMUM -84%) AND A MEAN REDUCTION OF LOW-DENSITY LIPOPROTEIN (LDL) OF -49% (MAXIMUM -87%) AT THE HIGHEST DOSE.

CRISPR THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 CLINICAL DATA FOR CTX310 DEMONSTRATING DEEP AND DURABLE ANGPTL3 EDITING, TRIGLYCERIDE AND LIPID LOWERING

-PRECLINICAL DATA PRESENTED AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) HIGHLIGHT A POTENTIAL BEST-IN-CLASS PROFILE-

CRISPR THERAPEUTICS PRESENTS NEW PRECLINICAL DATA FOR CTX460 DEMONSTRATING IN VIVO GENE CORRECTION OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) UTILIZING NOVEL SYNTASE EDITING PLATFORM

ZUG, SWITZERLAND AND BOSTON, OCT. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR THERAPEUTICS (NASDAQ: CRSP), A BIOPHARMACEUTICAL COMPANY FOCUSED ON CREATING TRANSFORMATIVE GENE-BASED MEDICINES FOR SERIOUS DISEASES, TODAY ANNOUNCED THE ACCEPTANCE OF AN ABSTRACT FOR ORAL PRESENTATION AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) 2025 ANNUAL CONGRESS, TAKING PLACE OCTOBER 7-10, 2025. THE PRESENTATION WILL INTRODUCE THE COMPANY'S NOVEL SYNTASE GENE EDITING TECHNOLOGY AND HIGHLIGHT ITS APPLICATION IN SINGLE-DOSE IN VIVO GENE CORRECTION TO TREAT ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), A RARE GENETIC DISORDER.

CRISPR THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) UTILIZING NOVEL SYNTASE GENE EDITING TECHNOLOGY AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) 2025 ANNUAL CONGRESS

CRISPR Therapeutics AG

CRSP

Price

Financial Reports

No items found.

Press Releases

CRISPR Therapeutics AG

CRSP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CRSP